Combined company begins trading on the Nasdaq Stock Market at a pro forma enterprise value of approximately $288 million, marking the arrival of a new pure-play regenerative medicine and longevity platform on the U.S. public markets
Combined company begins trading on the Nasdaq Stock Market at a pro forma enterprise value of approximately $288 million, marking the arrival of a new pure-play regenerative medicine and longevity platform on the U.S. public markets